Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Innovent will supply sintilimab for the collaborated clinical trial
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Highlights Mirvetuximab-based regimen promise
Subscribe To Our Newsletter & Stay Updated
